NEW
YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
Shareholders who purchased shares of REGN during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=123059&from=4
CLASS PERIOD: November 2,
2023 to October 30, 2024
ALLEGATIONS: The complaint alleges that during the class period, Defendants
issued materially false and/or misleading statements and/or failed
to disclose that: (1) Regeneron paid credit card fees to
distributors on the condition that distributors did not charge, one
of the Company's primary products, Eylea customers more to use a
credit card; (2) these payments subsidized the prices that
customers paid when using credit cards to purchase Eylea; (3) as a
result, Regeneron offered a price concession that lowered Eylea's
selling price; (4) because retina practices were sensitive to
higher prices when using credit cards to purchase anti-VEGF
medications, Regeneron's price concessions provided a competitive
advantage; (5) as a result of the foregoing, Regeneron misleadingly
boosted reported Eylea sales; (6) by failing to report its payment
of credit card fees as price concessions, Regeneron overstated the
ASP reported to federal agencies, thereby violating the False
Claims Act; and (7) as a result of the foregoing, defendants'
positive statements about the Company's business, operations, and
prospects were materially misleading and/or lacked a reasonable
basis.
DEADLINE: March 10, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=123059&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of REGN during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is March 10, 2025. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal
business practices. The Gross Law Firm is committed to ensuring
that companies adhere to responsible business practices and engage
in good corporate citizenship. The firm seeks recovery on behalf of
investors who incurred losses when false and/or misleading
statements or the omission of material information by a company
lead to artificial inflation of the company's stock. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-regeneron-pharmaceuticals-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-march-10-2025--regn-302352521.html
SOURCE The Gross Law Firm